Literature DB >> 16123432

Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.

Toshiro Sakuma1, Minoru Tanaka, Atsushi Mizota, Junji Inoue, Steve Pakola.   

Abstract

PURPOSE: To investigate the safety of intravitreal microplasmin in rabbits and to confirm previous findings of posterior vitreous detachment (PVD).
METHODS: Different doses of microplasmin, from 12.5 microg to 250 microg, in 0.1 mL balanced salt solution (BSS) were injected into the vitreous cavity of rabbit eyes to induce PVD. Fellow eyes were injected with the same volume of BSS. Slit-lamp biomicroscopy, ophthalmoscopic fundus examinations, A- and B-mode ultrasonography, and electroretinography were performed to assess the retina. Electroretinograms (ERGs) were recorded up to 90 days after injection. Morphologic alterations were assessed by light microscopy, scanning electron microscopy (SEM), and transmission (TEM) electron microscopy.
RESULTS: A slight aqueous flare and cells were observed in the anterior chamber after microplasmin and BSS injection. A slight inflammatory reaction was also observed transiently in the vitreous cavity. In control eyes, B-mode ultrasonography and SEM examination demonstrated that PVD did not develop after BSS injection. Intravitreal injections of 125 microg or greater of microplasmin induced complete PVD with an internal limiting membrane (ILM) devoid of vitreous collagen fibrils. Eyes injected with 12.5 microg microplasmin had partial PVD, and SEM showed residual fibrils covering the ILM. In all eyes, there was a transient reduction in the a- and b-waves of the ERG on days 2 through 7. The ERGs showed less effect with < 250 microg microplasmin.
CONCLUSIONS: Intravitreal injection of recombinant microplasmin in the rabbit induces no ERG or retinal ultrastructural abnormalities. Pharmacologic vitreolysis with this agent may be a useful adjunct to vitreous surgery and could be used to induce PVD without vitreous surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123432     DOI: 10.1167/iovs.04-1517

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.

Authors:  David T Goldenberg; Frank J Giblin; Mei Cheng; Shravan K Chintala; Michael T Trese; Kimberly A Drenser; Alan J Ruby
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

2.  Acute ocriplasmin retinopathy.

Authors:  Mark W Johnson; Abigail T Fahim; Rajesh C Rao
Journal:  Retina       Date:  2015-06       Impact factor: 4.256

3.  Foveola nonpeeling internal limiting membrane surgery to prevent inner retinal damages in early stage 2 idiopathic macula hole.

Authors:  Tzyy-Chang Ho; Chung-May Yang; Jen-Shang Huang; Chang-Hao Yang; Muh-Shy Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-23       Impact factor: 3.117

4.  ELLIPSOID ZONE MAPPING AND OUTER RETINAL CHARACTERIZATION AFTER INTRAVITREAL OCRIPLASMIN.

Authors:  Yuji Itoh; Justis P Ehlers
Journal:  Retina       Date:  2016-12       Impact factor: 4.256

Review 5.  Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.

Authors:  Yahiya Y Syed; Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

6.  Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels.

Authors:  F J Giblin; P A Quiram; V R Leverenz; R M Baker; Loan Dang; M T Trese
Journal:  Exp Eye Res       Date:  2008-09-18       Impact factor: 3.467

7.  Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels.

Authors:  Polly A Quiram; Victor R Leverenz; Robert M Baker; Loan Dang; Frauk J Giblin; Michael T Trese
Journal:  Retina       Date:  2007-10       Impact factor: 4.256

8.  Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up.

Authors:  Francisco Gómez-Ulla; Manuel F Bande; Maximino Abraldes
Journal:  Doc Ophthalmol       Date:  2015-11-06       Impact factor: 2.379

9.  Preservation of structure and immunoreactivity at the vitreoretinal interface of the rabbit eye.

Authors:  Bruce A Pfeffer; Steven A Bernstein; Stephen P Bartels
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-20       Impact factor: 3.117

Review 10.  Ocriplasmin for vitreoretinal diseases.

Authors:  Irena Tsui; Carolyn K Pan; Ehsan Rahimy; Steven D Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.